4CPS-193 Effectiveness and safety of intravenous ustekinumab intensification in Crohn’s disease with loss of response or partial response to subcutaneous therapy

• Published in: European journal of hospital pharmacy. Science and practice 2024-03, Vol.31 (Suppl 1), p.A144-A145
• Main Authors: Herrero Bermejo, S, Lobato Matilla, E, Gómez Costas, D, Somoza Fernández, B, Ruiz Briones, P, Ferris Villanueva, M, Montero Antón, MDP, Rioja Díez, Y, Carrillo Burdallo, A, Herranz Alonso, A, Sanjurjo Sáez, M
• Format: Article
• Language: English
• Subjects: Conflicts of interest; Crohn's disease; Monoclonal antibodies; Patients; Remission (Medicine); Section 4: Clinical pharmacy services
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2024-eahp.297

Background and ImportanceUstekinumab is approved for adult patients with moderately-severe active Crohn’s disease (CD) at a usual dosing schedule of 90 mg every 8 to 12 weeks subcutaneously. Some patients may experience a partial response or secondary loss of response. There is increasing evidence for patient rescue by shortening the subcutaneous administration interval, but very little evidence for intravenous intensification.Aim and ObjectivesTo evaluate the effectiveness and safety of treatment intensification with intravenous ustekinumab in adults with CD and loss of response to the standard subcutaneous regimen.Material and MethodsSingle-centre, descriptive, retrospective study including CD patients who intensified ustekinumab treatment to receive 130 mg intravenously every 4–6 weeks from January 2020 to August 2022.The clinical remission rate (defined as a Harvey-Bradshaw index (HBI)